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Introduction: Cardiovascular disease (CVD) prevalence is increasing in low- and middle-
income countries. Total risk assessment is key to prevention.
Methods: Studies and guidelines published between 1990 and 2013 were sought using
Medline database, PubMed, and World Health Organization report sheets. Search terms
included 'risk assessment' and 'cardiovascular disease prevention'. Observational studies
and randomized controlled trials were reviewed.
Results: The ideal risk prediction tool is one that is derived from the population in which it is
to be applied. Without national population-based cohort studies in sub-Saharan African
countries like Nigeria, there is no tool that is used consistently. Regardless of which one is
adopted by national guidelines, routine consistent use is advocated by various CVD preven-
tion guidelines.
Conclusions: In low-resource settings, the consistent use of simple tools like the WHO charts
is recommended, as the beneﬁt of a standard approach to screening outweighs the risk of
missing an opportunity to prevent CVD.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Cardiovascular disease (CVD) is a progressive consequence of
atherosclerosis that begins early in life with a long latency
period before the ﬁrst manifestation.1 It is the cause of death in
about a third of the world population.2 This mortality is
projected to increase to 24 million deaths by 2030.3 In Europe,
over 4.3 million deaths annually are due to CVD, half of which
is from coronary heart disease (CHD) and a third from stroke. It
imposes a considerable burden on the economy as it costs the
European Union about s192 billion annually.4 Eighty percent
of the CVD burden occurs in low- and middle-income
countries (LMIC).5 In Nigeria, although CVD lags behind* Corresponding author.
E-mail address: sandytom77@yahoo.com (S.N. Ofori).
http://dx.doi.org/10.1016/j.ihj.2015.07.004
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierinfectious disease as the commonest cause of death, it
accounts for higher age-speciﬁc mortality when compared
to developed countries.2,6 According to the Global Burden of
Disease study 2013, in all countries, ischemic heart disease
was the greatest contributor to death among middle-aged
individuals especially among men.2 Even in most countries in
sub-Saharan Africa, cardiovascular diseases including cardio-
myopathy were leading contributors to mortality burden in the
region.2 Apart from being leading causes of death, stroke and
ischemic heart disease were the top two causes of years of life
lost (an index of morbidity) in many regions of the world
including Central and East Asia.2
The underlying risk factors for CVD are similar worldwide,
as the INTERHEART study showed that nine modiﬁable risk B.V. All rights reserved.
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lack of regular physical activity, abdominal obesity, hyperten-
sion, abnormal lipids, diabetes mellitus, alcohol consumption,
and stress) accounted for more than 90% of the risk for incident
myocardial infarction.7 The increasing age of the population in
addition to the rising prevalence of obesity and diabetes
(especially among ethnic minorities) are important factors
that drive up the prevalence of CVD.8 Although improved
treatment modalities reduce mortality from CVD, the index
presentation may be with sudden death or for those who
survive an event, long-term disability. Furthermore, majority
of individuals with CVD are asymptomatic; therefore, preven-
tive measures remain mandatory.
In order to prevent CVD in an appropriate and cost-effective
manner, the total-risk approach is recommended.9,10 This
involves the assessment of an individual's risk of developing
CVD, taking into account several risk factors that may be
present. Treatment to reduce the risk is then instituted above a
pre-deﬁned threshold that is considered high-risk. It repre-
sents a paradigm shift from the traditional method of
screening for and treating single risk factors.9 This is because
moderate levels of several risk factors that interact multipli-
catively confer a higher absolute risk of CVD on an individual
than a markedly elevated level of one risk factor.11 Moreover,
assessments based on total risk leads to better CVD prevention
as was shown in a review of randomized controlled trials (RCT)
where treatment beneﬁt in terms of absolute risk reduction
was a function of an individual's pre-treatment total CVD risk
rather than the speciﬁc level of any single risk factor.12 Several
tools for estimating total cardiovascular risk are available and
recommended by national and international guidelines.1,9,13
They are available as paper charts or online calculators with
the latter incorporating more variables. Risk assessment is a
key component of national policies like Putting Prevention
First in the United Kingdom.13,14 In developing countries in
sub-Saharan Africa like Nigeria, the situation is different.
There have been no population-based cohort studies done, so
whatever information there is about cardiovascular risk
factors is obtained mostly from hospital-based and small
community cross-sectional studies. The effect of these risk
factors on cardiovascular outcomes in this environment
remains largely unknown. There are no national guidelines
on risk assessment at this time; therefore, in practice,
clinicians assess risk mostly from guidelines produced in
developed nations. This articles aims to review the various
tools available to assess and predict cardiovascular risk and
highlight areas that can be applied to low-resource settings.
2. Risk estimation, advantages, and
disadvantages of the risk estimation tools
Risk estimation aids a clinician to identify individuals at high
multifactorial risk for CVD and tailors the intensity of
interventions to baseline total cardiovascular risk. A risk
assessment tool that has been validated and evaluates
relevant non-modiﬁable and modiﬁable risk factors is required
to calculate the absolute risk. Absolute risk is determined by
the synergistic effect of all the cardiovascular risk factors
present and is deﬁned as the probability that an individual willhave a cardiovascular event in a deﬁned period, usually 10
years.9 Individuals at high absolute risk beneﬁt the most from
intervention.1,9,13 Some of the tools are not exactly accurate, as
other variables like diet and exercise are not included, so it
remains important to individualize any interventions.
Risk assessment of an individual starts with identifying his/
her risk factors, some of which may be modiﬁable. These
factors, their implications for health, and the recommended
goals should be discussed with them. The risk assessment
tools (in Table 1) available to estimate absolute risk vary
slightly in the risk factors they incorporate; therefore, the
calculated absolute risk will vary.1,9,13 Jackson et al. pointed
out that single risk factors like blood pressure (BP) and
cholesterol on their own have a minor effect on a patient's
absolute risk but in the presence of others can have a major
effect.12 In the Multiple Risk Factor Intervention Trial, at all
levels of BP and cholesterol, an additional risk factor like
smoking multiplied the absolute CVD risk even further.15
The use of equations to estimate CVD risk has been shown
to be better than clinical judgment alone.16 The tools include:
 Joint British Societies 2 (JBS2) risk calculator (based on the
Framingham risk score)
 Pooled Cohort Equations
 World Health Organization (WHO) charts
 The INTERHEART modiﬁable risk score
 SCORE (Systematic Coronary Risk Evaluation)
 QRISK2 risk calculator
 QRISK Lifetime cardiovascular risk calculator
 ASSIGN score (Scotland only)
2.1. JBS2
The JBS2 guidelines recommend risk assessment with the JBS2
cardiovascular risk prediction chart or calculator modeled on a
Framingham function which is based on the data derived from
middle class white Americans in the 70–80s.17 Its advantages
include that it is a well-established model, has been validated in
different populations, and includes a set of core risk factors, i.e.,
age, gender, smoking, total cholesterol: high-density lipoprotein
cholesterol ratio, and blood pressure while excluding diabetes.
Diabetics are considered high-risk and do not require risk
assessment. An important weakness of this risk model is that it
omits ethnicity.18 Although the risk can be adjusted by
multiplying with a constant, e.g., 1.5 for South-Asian origin,
the various South-Asian populations differ in their risk for
CVD.19 The electronic calculator incorporates these variables. In
addition, it assesses the risk of CHD alone and does not
encompass other CVD such as stroke. Currently in Europe,
Framingham-based risk scores overestimate risk, as CVD
mortality is declining, especially in people who reside in afﬂuent
areas.20The National Institute for Health and Clinical Excellence
recently withdrew its recommendation to use Framingham
equations as the tool of choice for risk assessment.21
2.2. Pooled Cohort Equations
These are sex- and race-speciﬁc Pooled Cohort Equations
developed from multiple, community-based large cohort
Table 1 – Some of the different risk estimation tools available with their relevant risk factor variables.
JBS2 QRISK2 ASSIGN JES5a WHO QRISK Lifetime
Data Based on FHS
and Framingham
Offspring Study
QRESEARCH
database
SHHEC
prospective
study
12 pooled
prospective
studies from 11
European
countries
Different
method not
based on
prospective data
QRESEARCH
database
Population and
sample type
General
population,
Framingham
Mass, U.S.
Volunteers
Health records of
general practice
attendees-not
random
Random sample
from general
population in
Scotland
Random samples
from general
population,
some
occupational
cohorts
Not applicable Health records of
general practice
attendees-not
random
Sample size 3969 men
4522 women
2.29 million 6540 men
6757 women
117,098 men
88,080 women
Not applicable 2.29 million
Calculates 10-year risk of
CVD events, risk
age
10-year risk of
CHD, stroke and
TIA
10-year risk of
CVD events
10-yr risk of CVD
mortality
10-year risk of
CVD events
CVD risk over a
person's
remaining
lifetime
Age (years) 30–75 30–84 30–74 40–65 20–75 30–84
Variables Age, sex, SBP,
DBP, TC, HDL,
TC/HDL,
TG, smoking,
glucose, central
obesity, S.A
origin, FHx, LVH
Sex, age, TC/
HDL, SBP,
smoking status,
diabetes, area-
based index of
deprivation,
family history,
BMI, anti-
hypertensive
treatment, CKD,
AF, RA
Current age,
gender, FHx,
diabetes,
cigarettes
smoked daily,
SBP, TC, HDL,
Scottish
postcode
Age, gender,
smoking, SBP,
TC, HDL
Age, gender,
smoking, SBP
 TC, diabetes
Sex, age, TC/HDL,
SBP, smoking
status, diabetes,
area-based index
of deprivation,
family history,
BMI, anti-
hypertensive
treatment,
previous CVD,
CKD, AF, RA
Formats Color charts,
online calculator
Online calculator Online calculator Color-coded
charts, Heart
Score-online and
CD electronic
versions
Color-coded
charts
Online calculator
Guidelines that
recommend
its use
JBS2 NICE guidelines
on lipid
modiﬁcation
SIGN European
guidelines on
CVD prevention
WHO guidelines
on CVD
prevention
JBS3 calculator
(not yet
published)
Adapted from: Cooney et al. (2009).32
AF, atrial ﬁbrillation; BP, blood pressure; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease (heart attack,
angina, stroke or transient ischemic attack); DBP, diastolic blood pressure; FHS, Framingham Heart Study; FHx, family history of premature
CVD; HDL, high density lipoprotein cholesterol; JBS, Joint British Societies; LDL, low density lipoprotein cholesterol; NICE, National Institute for
Health and Clinical Excellence; S.A origin, South Asian origin; SBP, systolic blood pressure; SHHEC, Scottish Heart Health Extended Cohort;
SIGN, Scottish Intercollegiate Network; RA, rheumatoid arthritis; TC, total cholesterol; TG, triglyceride; TIA, transient ischemic attack.
a The total risk is for fatal CVD.
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lifetime risk for 'hard' atherosclerotic CVD events for African-
American and White men and women 40–79 years of age.22
The data from which this tool was derived are mostly recent
from the 1990s. The variables included in this equations are
age, total and HDL-cholesterol, systolic BP (including treated or
untreated status), diabetes, and current smoking status. The
end-point of hard atherosclerotic events is deﬁned as the ﬁrst
occurrence of nonfatal myocardial infarction or CHD death, or
fatal or nonfatal stroke. Patients are considered to be at
‘‘elevated’’ risk if the Pooled Cohort Equations predicted risk is
≥7.5%. This equation is proposed to replace the traditional
Framingham risk equation. Its inclusion of stroke as an
endpoint is advantageous because in groups like women and
African-Americans, stroke occurs earlier than heart attack.23
Thus, this is appropriate for assessing their risk. This tool isvalidated for use only in Caucasians and African-American
blacks, so outside these populations it may not accurately
predict CVD risk. In validation studies using three separate
cohorts, this equation was found to overestimate risk only in
high-risk patients who would require statin therapy regard-
less. In lower risk patients in order to buffer the effect of risk
overestimation, the treatment threshold is 7.5% as opposed to
5%, which is the level of risk in clinical trials above which statin
therapy is beneﬁcial.
2.3. WHO
The World Heart and Stroke Forum classiﬁes risk factors into
major, underlying, and emerging. They suggest that differ-
ences in the underlying risk factors (obesity, poor diet, physical
inactivity, family history of premature CVD, ethnicity, stress)
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variability of absolute risk predicted by the major risk factors.24
Different regions in the world differ in their distribution of CVD
risk factors, and in most LMICs, there are no population-
derived cohort data. The risk factors considered include age,
systolic blood pressure, smoking status, blood pressure
treatment status, history of diabetes mellitus, and cholesterol.
In resource-poor settings where laboratory tests are not
readily available, another chart for risk prediction was
provided which excluded cholesterol. Due to the absence of
population derived cohort data, the prediction charts for each
sub-region were developed using the modeling approach.10
The modeling method by which the charts were derived makes
it a weaker risk estimation system; moreover, it has not been
compared with any of the standard prediction rules nor
validated in any cohort. Having said that however, a study by
Gaziano et al. compared the use of non-laboratory-based data
with laboratory-based data to estimate the 10-year risk of
incident cardiovascular events (myocardial infarction, heart
failure, stroke, angina) in participants in the National Health
and Nutrition Examination Survey (NHANES) study.25 Using
the same risk factors in the WHO charts with the substitution
of BMI for cholesterol in the non-laboratory-based model, they
found a very close correlation between the two models in risk
prediction. Furthermore, in another study, Gaziano et al.
compared this non-laboratory-based risk model with six other
standard risk scoring tools (including three versions of
Framingham risk, SCORE for high- and low-risk countries,
and CUORE) in a cross-section of 14,772 South African adults
using data collected between 1987 and 2009.26 The study
population consisted of thirteen separate cohorts with a wide
distribution of absolute risk levels. They found a high
correlation between the non-laboratory-based model and
the six standard risk scores. In addition, based on a risk
threshold that corresponded to 10-year 2008 Framingham risk
of more than 20%, the non-laboratory-based score agreed to a
high degree such that 92.3% of men and 94.0% of women were
similarly characterized as high or low risk by both risk scores.
The agreement was even higher when compared to the SCORE
risk tool. Their ﬁndings suggest that the WHO charts may be
used with less anxiety to predict risk in low-resource settings.
In these settings, multiple factors affect the feasibility of CVD
prevention apart from poorly funded healthcare. Distances
patients travel to access healthcare may make it impossible to
present early in the day for a fasting blood test, so the use of
this non-laboratory-based model to predict CVD risk in one
clinic visit remains an attractive choice in these settings.
However, the WHO charts do not include factors like
obesity and family history of premature CVD and, therefore,
has the potential to underestimate an individual's actual risk.
The speciﬁc threshold for intervention is based on the
available health care resources in each sub-region.
2.4. The INTERHEART modiﬁable risk score
This is a risk score that has the potential for use in resource-
limited settings with several advantages even over the WHO
risk assessment charts. This score is derived from a large
multi-ethnic case–control study involving 19,470 individuals.27
Two-thirds of the data set was used to derive the score, whilethe other one-third was used for internal validation. It is
relatively simple to use and includes variables like apolipo-
proteins, smoking status (current or ex-smoker), second-hand
smoke exposure, hypertension, and diabetes. Where facilities
for cholesterol testing are unavailable, there is an option of a
non-laboratory-based version, which includes age, sex, smok-
ing, diabetes, high blood pressure, family history of heart
disease, waist-to-hip ratio, psychosocial factors, diet, and
physical activity. Although it is generalizable to various
populations, it has the distinct disadvantage that it was
derived not from a cohort study but a case control study.
Therefore, it was not developed as a score that 'predicted' risk.
On the other hand, it included a good number of women,
individuals from low-income countries, and people in younger
age groups who are otherwise underrepresented in cohort
studies of CVD events. The end result of atherosclerosis
comprises events including stroke, acute coronary syndromes,
and peripheral artery disease; the ideal tool would thus be one
that had the ability to predict 'total CVD' events unlike this one
that predicts incident myocardial infarction (MI) only. Howev-
er, in the development of this score, the outcome of incident MI
was deﬁned precisely in the INTERHEART study7 and thus is
easily standardized. In the derivation of risk scores, propor-
tional hazards models are preferred to logistic regression, but
the creators of the INTERHEART risk score used unconditional
logistic regression to minimize loss of data. The discrimination
of this risk score, i.e., its ability to separate those who will
develop incident MI from those who will not, was fair at 0.71
[95% conﬁdence interval (CI): 0.70, 0.72]. Furthermore, this
score has been externally validated in several studies.28,29 Of
note recently was the use of this score in the large multi-
country PURE study that included 156,424 persons from 628
urban and rural communities to quantify the risk factor
burden in various populations in high-, middle-, and low-
income countries. It reliably predicted cardiovascular events
over a mean over follow-up of 4.1 years.30
2.5. SCORE
The SCORE project is a risk scoring system derived from pooled
cohort studies across 11 European countries and is recom-
mended by the European guidelines on CVD prevention. Based
on a larger, more current cohort, it is more likely to reﬂect the
baseline CVD risk across Europe better than the JBS2
calculator.18 Its other advantages include that it is an easy
tool to use, is based on the European guidelines, and depicts
the relative contribution of modiﬁable risk factors in a
graphical format. It also shows how risk increases with age
and the relative risk chart helps to illustrate how a young
person with a low absolute risk may be at a substantially
higher and reducible relative risk.18 It has a simple chart
format, and charts have been shown to enhance the use of risk
assessment tools in clinical practice.31 In addition, its
inclusion of the integer value as well as color codes for the
different levels of risk offers an advantage over charts like the
JBS2 that are color-coded only.32 In developing this SCORE, the
10-year risk of death was the end-point allowing ease of
ascertainment across the various cohorts used. A disadvan-
tage of this is that in an asymptomatic individual conveying
his/her risk as a fatality might have a negative effect. Besides,
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and not validated.33 Also, excluding the risk of morbidity might
be a disadvantage since most CVDs are non-fatal events.32
2.6. QRISK2
The QRISK2 was derived from a large cohort from the primary
care database (QRESEARCH) in England and Wales. It has been
validated in various cohorts, and in an external validation
study using The Health Improvement Network database, it
was better than the Framingham-based scores in estimating
risk among individuals in a UK population.34 Ethnicity
inﬂuences cardiovascular risk, so using the QRISK2 may help
to reduce health inequalities that arise when people are
misclassiﬁed using tools that exclude ethnicity.34 QRISK2
works over a wider age range than the JBS2 and SCORE
calculators, so this is an added advantage. The additional
variables in QRISK2 (Table 1) are easily obtained and their
inclusion improves its ability to discriminate between people
who will develop the endpoint from those who will not.
Though there is little improvement in the function of a model
upon addition of variables after conventional risk factors,
D'Argostino and colleagues suggest that if the cost of obtaining
new variables is low, it may be well worth including in the
prediction model.35 In addition, as the population changes,
this tool can be regularly updated improving its durability.
Some disadvantages of this algorithm include the non-
standardization of outcome measurements which were based
on doctors' diagnosis recorded on a computer, the baseline risk
factors were measured at different times during the observa-
tion period, and many missing data (e.g., lipids) were included
in the analysis.32 In addition, the inclusion of postcode as a
measure of deprivation may limit the applicability of this tool
in areas outside the UK.
2.7. QRISK lifetime
The QRISK lifetime calculator was developed from the
QRESEARCH database. Cardiovascular 'life-time risk' estima-
tion has the potential to improve risk prediction, as it
estimates the absolute risk of an individual developing CVD
over their remaining lifetime based on their risk factor
proﬁle.36 With this, younger people who have low or
intermediate absolute risk (as age is a key driver of absolute
CVD risk), but a high lifetime risk can be identiﬁed.36 Moreover,
younger patients have a longer lifetime in which CVD may
manifest and earlier intervention may lead to greater beneﬁt.37
This is because the duration of exposure to a risk factor is
probably more important than a 'snapshot' summary of its
current level.38 Its other advantages lie in its potential as a
public-health awareness tool, as awareness of risk of a disease
may lead to better adoption of prevention strategies and the
new Joint British Societies guidelines on CVD prevention (JBS3)
will focus on this approach. Also, when compared to the
lifetime-risk of other diseases such as cancer, its huge impact
on public health may be better understood.39 One disadvan-
tage is that its applicability to individual patients is question-
able as estimates of lifetime risk represent the average
experience derived from large cohorts. In addition, some
CVD risk factors, e.g., smoking, increase the risks of death fromnon-CVD causes and may in fact reduce the risk of dying from
CVD.39 It only estimates 'hard' endpoints like death and non-
fatal MI, whereas outcomes like quality of life and disability
adjusted life years are becoming increasingly important with
better treatment modalities. Furthermore, the purpose of risk
estimation is to make a decision on actions to be taken presently
and the 10-yr absolute risk estimation identiﬁes individuals
who stand to beneﬁt the most from intervention in the short
term, whereas lifetime risk may lead to 'overtreatment'. This is
because most people will have a high lifetime risk for CVD;
therefore, in considering the need for primary prevention,
which is the priority in developing countries with an emerging
CVD epidemic, the lifetime risk alone is not appropriate.37
2.8. ASSIGN
The ASSIGN score estimates the risk of total CVD (fatal and non-
fatal) over 10 years based on a cohort of Scottish people and is
recommended by Scottish Intercollegiate Guidelines Network. It
was developed as an alternative to the Framingham equations
that was inaccurate in estimating risk in their population. The
cut-point for intervention is 20% like the JBS2; however, it differs
from it by including social deprivation, family history of
premature CVD, and number of cigarettes smoked and not just
smoking status. It also gives lower absolute values and it has not
been validated in a non-Scottish population.32
2.9. Other methods and markers to estimate CVD risk
Almost half of all CVD deaths occur in individuals at
intermediate-risk and a proportion of individual variance in
risk remains unexplained.40 Therefore, there is continued
interest in the search for other methods and markers to
improve the predictive ability of current risk estimation
tools.37 These include biologic, genetic, or imaging modalities.
One measure to determine the discriminative ability of a risk
prediction model is the C statistic. Values between 0.7 and 0.8
are considered acceptable and a risk marker requires a large
odds ratio or relative risk to meaningfully increase the C
statistic.41 For new markers to improve the performance of
current models, they should be inexpensive, easily measur-
able, and independently associated with CVD.18 Most new
markers correlate highly with traditional risk factors and do
not increase the C statistic signiﬁcantly when added to the
existing risk models.37
Of all the biologic markers (N-terminal pro-brain natriuretic
peptide, homocysteine, ﬁbrinogen, lipoprotein-associated
phospholipase 2, etc.), C-reactive protein (CRP), a circulating
marker of inﬂammation, has been extensively studied and is
the most consistently associated with CHD. It improved risk
prediction (as much as lipids) when added to the Framingham
score in the Women's Health Study and was useful in
reclassifying individuals at moderate risk, but in the British
Women's Heart and Health Study, it was not associated with
CVD and did not improve prediction.41,42 One reason for this
difference may be that the participants in the former were
younger and CRP is a marker of early atherosclerosis. The
contribution of ten biomarkers (including CRP) to CHD was
assessed in the Framingham cohort. Higher multi-marker
scores correlated with major cardiovascular events and deaths
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conventional risk factors.43 A systematic review concluded
that CRP improved risk stratiﬁcation or reclassiﬁcation when
added to established risk factor-models but in a small and
inconsistent manner.44 The current European guidelines give a
weak recommendation for its assessment in individuals at
moderate risk to inﬂuence clinical decisions.1
Family history of premature CVD is an important risk factor
suggesting a genetic component to CVD. Genetic abnormalities
can affect intermediate phenotypes like cholesterol, or directly
inﬂuence CVD. However, the relationship between genetics and
CVD is complex and individual genes identiﬁed in genome-wide
association studies to be associated with CVD have small
effects.45 The ability of two genetic risk scores comprising all
published single nucleotide polymorphisms, to predict total
CVD was tested in participants of the Women's Genome Health
Study. The scores were associated with cardiovascular events
but did not improve cardiovascular risk prediction beyond
traditional risk factors.46There is currently insufﬁcient evidence
to include them in clinical risk prediction tools.
Imaging modalities enable assessment of subclinical
atherosclerosis. Coronary artery calcium (CAC) score detected
by computed-tomography scanning indicates the presence of
an atherosclerotic plaque in the artery and correlates with the
severity of atherosclerosis. In a meta-analysis of four
prospective studies with a mean follow-up of 3.6 years, CAC
score predicted CHD events after adjusting for established risk
factors.47 Results from the Multi-Ethnic Study of Atheroscle-
rosis went further to show that adding CAC to a risk model
based on the traditional risk factors correctly reclassiﬁed 23%
and 13% of the participants into high- and low-risk categories
respectively and this beneﬁt was most in the intermediate-risk
group.48 It is a non-invasive test, but the costs and risk of
radiation exposure (however minimal) remain signiﬁcant
limitations to its routine use. Vascular ultrasound of the
carotid arteries can be used to measure the carotid intima-
media thickness (CIMT), characterize atherosclerotic plaques,
and measure arterial stiffness.1 As the CIMT rises above
0.9 mm, the relative risk of CVD increases, even after adjusting
for traditional risk factors, especially in women. Others include
the measurement of ankle-brachial index and exercise
electrocardiography. While the current European guidelines
recommend that these imaging modalities may be reasonable
for risk assessment in individuals at moderate risk, the 2013
ACC/AHA Cardiovascular Risk Guideline does not recommend
its use for routine measurement in clinical practice for risk
assessment for a ﬁrst ASCVD event.1,22
Generally, although new markers may help to reclassify
people at moderate risk above or below a chosen intervention
threshold, it remains important to determine the potential
treatment impact of reclassiﬁcation and whether the health
beneﬁt of reclassiﬁcation outweighs the added cost and risks
of biomarker measurement as pointed out by Pletcher and
Pignone.37,49
3. Communicating risk
A vital part of risk prediction is communication. Individuals
need to understand the meaning of their calculated CVD risk inorder to be motivated to adopt healthy life-changing behaviors
and treatments. Risk can be communicated in a sensitive
manner using concepts like relative risk, risk age/heart age,
rate advancement period, and lifetime risk.
The absolute risk of an individual can be compared with
that of a person in the same age group but with normal levels
of risk factors. This is referred to as relative risk and its enables
the individual understand his/her risk relative to their peers
not necessarily as a basis for treatment decisions.32 In a cluster
RCT, risk depicted graphically as relative risk in combination
with strategies to modify risk factors positively inﬂuenced the
behavior of both the physicians and patients in the interven-
tion arm. Follow-up after six months showed that they had
lower blood pressures and their Framingham risk score was
signiﬁcantly 10% lower compared to those who received usual
care.50 However, the appropriateness of recalculating risk after
intervention is questionable.
Heart age or risk age is used to determine if an individual,
who has a low or intermediate risk will beneﬁt from early
intervention. It is the age of a person with the same predicted
risk but with all other risk factor levels in normal ranges.35 The
SCORE and QRISK2 calculators give estimates of risk age.
Individuals may ﬁnd it easier to comprehend the concept of
having a heart that is several years 'older' than their
chronological age and this knowledge may impact on their
decision to modify their lifestyle. One published RCT found
that among 413 participants, risk perception was closer to
actual risk in those randomized to receive their CVD risk
expressed as heart age compared to those who got absolute
risk as a percentage and the intention to change was mediated
by the higher emotional impact it generated.51 The extent to
which these ﬁndings are generalizable, however, is question-
able, as the participants were recruited online and may not be
representative of the average person with CVD risk factors.
Rate advancement period is the difference between a
person's current age and risk age on the relative risk chart.
This is the average number of years the individual can expect
to lose due to the premature onset of CVD.32 This simple way to
communicate risk was shown to be effective in conveying the
beneﬁts of quitting smoking in older smokers in a population-
based cohort study.52 Lifetime risk has been discussed above.
4. Conclusion
The overall objective of the risk assessment strategies
discussed above is reducing the risk of CVD. It enables
clinicians identify and stratify individuals at risk for CVD
and aids communication with the individual to help them
understand the importance of lifestyle modiﬁcation and drug
therapy. Any of the validated tools can be used but they differ
in various ways like the methods by which they were derived,
variables included and deﬁned endpoints. However, they are
all based on the same principle and using them routinely in
practice is more important than decisions regarding which
tool to use. Region- or country-speciﬁc tools derived from
cohort data are ideal but in developing countries like Nigeria
without cohort data, the consistent use of either simple
laboratory-based or non-laboratory-based tools like the WHO
charts or INTERHEART modiﬁable risk score remains the best
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 9 1 – 3 9 8 397choice. This is because the beneﬁt of a standard approach to
screening outweighs the risk of missing an opportunity to
prevent CVD.
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